Cited by 245Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group

Open access

Chou, Alexander J., Kleinerman, Eugenie S., Krailo, Mark D., Chen, Zhengjia, Betcher, Donna L., Healey, John H., Conrad, Ernest U., Nieder, Michael L., Weiner, Michael A., Wells, Robert J., Womer, Richard B., Meyers, Paul A., on behalf of the Children's Oncology Group·2009·Cancer

DOI 10.1002/cncr.24566PMC PMC2783515

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The addition of liposomal muramyl tripeptide phosphatidylethanolamine (MTP‐PE) to chemotherapy has been shown to improve overall survival in patients with nonmetastatic osteosarcoma (OS). The authors report the results of addition of liposomal MTP‐PE to chemotherapy for patients with metastatic OS. METHODS: Intergroup‐0133 was a prospective randomized phase 3 trial for the treatment of newly diagnosed patients with OS. The authors compared 3‐drug chemotherapy with cisplatin, doxorubicin, and high‐dose methotrexate (Regimen A) to the same 3 drugs with the addition of ifosfamide (Regimen B). The addition of liposomal MTP‐PE to chemotherapy was evaluated. RESULTS: Five‐year event‐free survival (EFS) for patients who received liposomal MTP‐PE (n = 46) was 42% versus 26% for those who did not (n = 45) (relative risk for liposomal MTP‐PE, 0.72; P = .23; 95% confidence interval [CI], 0.42‐1.2). The 5‐year overall survival for patients who received MTP‐PE versus no MTP‐PE was 53% and 40%, respectively (relative risk for liposomal MTP‐PE, 0.72; P = 0.27; 95% CI, 0.40‐1.3). The comparison of Regimen A with Regimen B did not suggest a difference for EFS (35% vs 34%, respectively; relative risk for Regimen B, 1.07; P = .79; 95% CI, 0.62‐1.8) or overall survival (52% vs 43%, respectively; relative risk for Regimen B, 1.1, P = .75; 95% CI, 0.61‐2.0). CONCLUSIONS: When the metastatic cohort was considered in isolation, the addition of liposomal MTP‐PE to chemotherapy did not achieve a statistically significant improvement in outcome. However, the pattern of outcome is similar to the pattern in nonmetastatic patients. Cancer 2009. © 2009 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.24566

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
The Statistical Analysis of Failure Time Data
Young, W. R. (1981) · Journal of Quality Technology · doi:10.1080/00224065.1981.11978770 · Cited by 1,717
Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Self-citation
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citation
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy
Bacci, G., Longhi, A., Versari, M., Mercuri, M., Briccoli, A., & Picci, P. (2006) · Cancer · doi:10.1002/cncr.21724 · Cited by 567
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Applewhite, A., Sun, M., & LaQuaglia, M. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.449 · Cited by 389
Self-citation
Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol.
Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294
Self-citation
Metastatic osteosarcoma at diagnosis
Mialou, V., Philip, T. O., Kalifa, C., Pérol, D., Gentet, J., Marec‐Bérard, P., Pacquement, H., Chastagner, P. B., Defaschelles, A.-S., & Hartmann, O. (2005) · Cancer · doi:10.1002/cncr.21263 · Cited by 283
Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide
MacEwen, E. G., Kurzman, I. D., ROSENTHAL, R. C., Smith, B. W., Manley, P. A., Roush, J. K., & Howard, P. E. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.12.935 · Cited by 227

Show all 29 references

Sorted by citations

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Current and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. B., Lewis, V. O., & Gorlick, R. G. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 691
Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551
Self-citation
Nanomedicine review: clinical developments in liposomal applications
Beltran-Gracia, E., López-Camacho, A., Higuera‐Ciapara, I., Velázquez-Fernández, J. B., & Vallejo‐Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 544
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up
Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513
Osteosarcoma Overview
Lindsey, B. A., Markel, J., & Kleinerman, E. S. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 490
Self-citation
Review of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 397
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 300
Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy
Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G. E., Santucci, A., Vermi, W., & Giurisato, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155207 · Cited by 280
New targets and approaches in osteosarcoma
Gill, J. B., Ahluwalia, M., Geller, D., & Gorlick, R. G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 274
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 285
Osteosarcoma: A comprehensive review of management and treatment strategies
Jafari, F., Javdansirat, S., Sanaie, S., Naseri, A., Shamekh, A., Rostamzadeh, D., & Dolati, S. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151654 · Cited by 253
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Future Directions in the Treatment of Osteosarcoma
Smrke, A., Anderson, P. M., Gulia, A., Gennatas, S., Huang, P. H., & Jones, R. L. (2021) · Cells · doi:10.3390/cells10010172 · Cited by 225
An update on chemotherapy for osteosarcoma
Ferrari, S. M., & Serra, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1102226 · Cited by 212
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
PosthumaDeBoer, J., Witlox, A. M. A., Kaspers, G. J. L., & van Royen, B. J. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9384-x · Cited by 194
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma
Dumars, C., Ngyuen, J.-M., Gaultier, A., Lanel, R., Corradini, N., Gouin, F., Heymann, D., & Heymann, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13055 · Cited by 183
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma
Roth, M. E., Linkowski, M., Tarim, J., Piperdi, S., Sowers, R. S., Geller, D., Gill, J. B., & Gorlick, R. G. (2013) · Cancer · doi:10.1002/cncr.28461 · Cited by 174
Epidemiology and therapies for metastatic sarcoma
Reed, D. R., Amankwah, & Conley, A. P. (2013) · Clinical Epidemiology · doi:10.2147/clep.s28390 · Cited by 154
Advances in the management of osteosarcoma
Bielack, S., Hecker‐Nolting, S., Blattmann, C., & Kager, L. (2016) · F1000Research · doi:10.12688/f1000research.9465.1 · Cited by 152
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Harris, M. A., & Hawkins, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073817 · Cited by 143
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes
Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
Meyers, P. A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.69 · Cited by 130
Self-citation
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
Shaikh, A. B., Li, F., Li, M., He, B., He, X., Chen, G., Guo, B., Li, D., Jiang, F., Dang, L., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040506 · Cited by 124
Review of mifamurtide in the treatment of patients with osteosarcoma
Kager, L., Pötschger, U., & Bielack (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5688 · Cited by 124
Current and Emerging Targets in Immunotherapy for Osteosarcoma
Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · Journal of Oncology · doi:10.1155/2019/7035045 · Cited by 123
Mifamurtide
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 118
The role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 113
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ
Pahl, J. H. W., Kwappenberg, K. M. C., Varypataki, E. M., Santos, S. J., Kuijjer, M. L., Mohamed, S., Wijnen, J., van Tol, M. J. D., Cleton-Jansen, A., Egeler, R. M., et al. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-27 · Cited by 101
Emerging drugs for high-grade osteosarcoma
Hattinger, C. M., Pasello, M., Ferrari, S., Picci, P., & Serra, M. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.505603 · Cited by 99
Advances in emerging drugs for osteosarcoma
Hattinger, C. M., Fanelli, M., Tavanti, E., Vella, S., Ferrari, S. M., Picci, P., & Serra, M. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1051965 · Cited by 94
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
Zhang, B., Zhang, Y., Li, J., Lu, X., Lu, X., & Zhang, Y. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-1576-0 · Cited by 95
The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures
Chen, L., Oke, T. F., Siegel, N. M., Cojocaru, G., Tam, A. J., Blosser, R. L., Swailes, J., Ligon, J. A., Lebid, A., Morris, C. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3416 · Cited by 92
Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90
Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors
Green, D. M., Kun, L. E., Matthay, K. K., Meadows, A. T., Meyer, W. H., Meyers, P. A., Spunt, S. L., Robison, L. L., & Hudson, M. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24487 · Cited by 92
Self-citation
Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data
Ren, H., Sun, L., Li, H., & Ye, Z. (2015) · BioMed Research International · doi:10.1155/2015/160835 · Cited by 88
Bisphosphonates Inhibit Osteosarcoma-Mediated Osteolysis Via Attenuation of Tumor Expression of MCP-1 and RANKL
Ohba, T., Cole, H., Cates, J., Slosky, D., Haro, H., Ando, T., Schwartz, H. S., & Schoenecker, J. G. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2182 · Cited by 84
Origin and Therapies of Osteosarcoma
Moukengué, B., Lallier, M., Marchandet, L., Baud’huin, M., Verrecchia, F., Ory, B., & Lamoureux, F. (2022) · Cancers · doi:10.3390/cancers14143503 · Cited by 92
Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma
van Oosterwijk, J. G., Anninga, J., Gelderblom, H. A. J., Cleton-Jansen, A., & Bovée, J. V. M. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.07.012 · Cited by 81
Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2020) · Cancers · doi:10.3390/cancers12071758 · Cited by 82
Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma
Meyers, P. A., & Chou, A. J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_17 · Cited by 79
Self-citation
Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma
Wang, Z., Wang, Z., Li, B., Wang, S., Chen, T., & Ye, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01114 · Cited by 77
Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments
Anderson, P. M., Meyers, P. A., Kleinerman, E. S., Venkatakrishnan, K., Hughes, D. P. M., Herzog, C. E., Huh, W. W., Sutphin, R. M., Vyas, Y. M., Shen, V., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24686 · Cited by 75
Self-citation
Clinical cancer nanomedicines
Pallares, R. M., Barmin, R. A., Wang, A., Kiessling, F. M., & Lammers, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113991 · Cited by 81
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group
Goldsby, R. E., Fan, T. M., Villaluna, D., Wagner, L. M., Isakoff, M. S., Meyer, J. S., Randall, R. L., Lee, S. C. L., Kim, G., Bernstein, M. L., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.018 · Cited by 72
Self-citation
Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis
Chen, J., Sun, M., Hua, Y., & Cai, Z. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1644-0 · Cited by 69
Managing sarcoma: where have we come from and where are we going?
Bleloch, J., Ballim, R. D., Kimani, S., Parkes, J., Panieri, E., Willmer, T., & Prince, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017728927 · Cited by 69
Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality
Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68
The Current and Future Therapies for Human Osteosarcoma
Lamplot, J. D., Denduluri, S. K., Qin, J., Li, R., Liu, X., Zhang, H., Chen, X., Wang, N., Pratt, A., Shui, W., et al. (2013) · Current Cancer Therapy Reviews · doi:10.2174/1573394711309010006 · Cited by 67
Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma
Fu, Y., Lan, T., Cai, H., Lu, A., & Yu, W. (2018) · Medicine · doi:10.1097/md.0000000000010741 · Cited by 68
Risk Factors, Prognostic Factors, and Nomograms for Distant Metastasis in Patients With Newly Diagnosed Osteosarcoma: A Population-Based Study
Chen, B., Zeng, Y., Liu, B., Lu, G., Xiang, Z., Chen, J., Yan, Y., Zuo, Z., Lin, Y., & Ma, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.672024 · Cited by 68
Immunotherapy of Childhood Sarcomas
Roberts, S. S., Chou, A. J., & Cheung, N. V. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00181 · Cited by 65
Self-citation
Therapeutic Targets for Bone and Soft-Tissue Sarcomas
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010170 · Cited by 66
Surgical treatment of pulmonary metastases in pediatric solid tumors
Heaton, T. E., & Davidoff, A. M. (2016) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2016.09.001 · Cited by 63
Drugs in early clinical development for the treatment of osteosarcoma
Heymann, M., Brown, H. K., & Heymann, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237503 · Cited by 65
Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease
Harrison, D. J., & Schwartz, C. L. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0464-2 · Cited by 63
Current Treatment Considerations for Osteosarcoma Metastatic at Presentation
Tsukamoto, S., Errani, C., Angelini, A., & Mavrogenis, A. F. (2020) · Orthopedics · doi:10.3928/01477447-20200721-05 · Cited by 59
Sarcoma Immunotherapy: Past Approaches and Future Directions
D’Angelo, S. P., Tap, W. D., Schwartz, G. K., & Carvajal, R. D. (2014) · Sarcoma · doi:10.1155/2014/391967 · Cited by 62
Sarcomas of Bone
Anderson, M. E., Randall, R. L., Springfield, D. S., & Gebhardt, M. C. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00092-8 · Cited by 59
Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma
Meyers, P. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_11 · Cited by 61
Self-citation
Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection
Aleynick, M., Svensson‐Arvelund, J., Flowers, C. R., Marabelle, A., & Brody, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1800 · Cited by 64
Targeting Glycoprotein NMB With Antibody‐Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
Roth, M. E., Barris, D. M., Piperdi, S., Kuo, V. F.-H., Everts, S., Geller, D., Houghton, P. J., Kolb, E. A., Hawthorne, T. R., Gill, J. B., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25688 · Cited by 58
The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats
Zabielska-Koczywąs, K. A., & Lechowski, R. (2017) · Molecules · doi:10.3390/molecules22122167 · Cited by 58
Bone sarcomas in the immunotherapy era
Heymann, M., Schiavone, K., & Heymann, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14999 · Cited by 60
Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma
Hao, H., Chen, L., Huang, D., Ge, J., Qiu, Y., & Hao, L. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12536 · Cited by 57
Immunotherapeutic Approaches to Sarcoma
Burgess, M. A., & Tawbi, H. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0345-5 · Cited by 55
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi, M., Pilavaki, P., Constantinidou, A., & Stylianopoulos, T. (2022) · Theranostics · doi:10.7150/thno.72800 · Cited by 59
Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients
Li, X., Chen, Y., Liu, X., Zhang, J. C., Xu, H., Teng, G., & Yu, D. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.01.006 · Cited by 56
Current questions in bone sarcomas
Strauss, S. J., & Whelan, J. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000456 · Cited by 49
Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma
Brard, C., Piperno-Neumann, S., Delaye, J., Brugières, L., Hampson, L. V., Teuff, G. L., Deley, M. L., & Gaspar, N. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025877 · Cited by 48
Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2
Meazza, C., Cefalo, G., Massimino, M., Daolio, P. A., Pastorino, U., Scanagatta, P., Morosi, C., Podda, M. G., Ferrari, A., Terenziani, M., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-1052-9 · Cited by 47
Strategies and developments of immunotherapies in osteosarcoma
WAN, J., Zhang, X., Liu, T., & Zhang, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.3962 · Cited by 46
Molecular pathogenesis and therapeutic strategies of human osteosarcoma
Denduluri, S. K., Wang, Z., Yan, Z., Wang, J., Wei, Q., Mohammed, M. K., Haydon, R. C., Luu, H. H., & He, T. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.29.20150075 · Cited by 45
Local Control of Soft Tissue and Bone Sarcomas
Crompton, J. G., Ogura, K., Bernthal, N. M., Kawai, A., & Eilber, F. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2717 · Cited by 45
Treatment of Bone Tumors
Rajani, R., & Gibbs, C. P. (2011) · Surgical pathology clinics · doi:10.1016/j.path.2011.07.015 · Cited by 42
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements
Adewuyi, E. E., Chorya, H. P., Muili, A. O., Moradeyo, A. A., Kayode, A. T., Naik, A., Odedele, J. T., & Obasanjo, O. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104575 · Cited by 42
Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis
Li, S., Yang, Q., Wang, H., Wang, Z., Zuo, D., Cai, Z., & Hua, Y. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1066 · Cited by 40
Translation of peptidoglycan metabolites into immunotherapeutics
Griffin, M. E., Hespen, C. W., Wang, Y., & Hang, H. C. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1095 · Cited by 41
Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review
Jimmy, R., Stern, C., Lisy, K., & White, S. (2017) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2016-003105 · Cited by 39
Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and c-Jun activation
Kany, S., Woschek, M., Kneip, N., Sturm, R., Kalbitz, M., Hanschen, M., & Relja, B. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4288 · Cited by 39
LncRNA MEG3 negatively modified osteosarcoma development through regulation of miR‐361‐5p and FoxM1
Shen, B., Zhou, N., Hu, T., Zhao, W., Wu, D., & Wang, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28026 · Cited by 38
Immune-Based Therapies for Sarcoma
Pollack, S. M., Loggers, E. T., Rodler, E. T., Yee, C., & Jones, R. L. (2011) · Sarcoma · doi:10.1155/2011/438940 · Cited by 37
Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models
Rodrigues, J., Sarmento, B. F. C. C., & Pereira, C. L. (2022) · In vitro models · doi:10.1007/s44164-022-00008-x · Cited by 41
L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.
Biteau, K., Guiho, R., Chatelais, M., Taurelle, J., Chesneau, J., Corradini, N., Heymann, D., & Rédiní, F. (2016) · PubMed Central · Cited by 36
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment
Venkatakrishnan, K., Liu, Y., Noe, D. A., Mertz, J., Bargfrede, M., Marbury, T. C., Farbakhsh, K., Oliva, C., & Milton, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12260 · Cited by 35
A 20-year retrospective analysis of CT-based pre-operative identification of pulmonary metastases in patients with osteosarcoma: A single-center review
Heaton, T. E., Hammond, W. J., Farber, B. A., Pallos, V., Meyers, P. A., Chou, A. J., Price, A. P., & LaQuaglia, M. P. (2016) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2016.10.034 · Cited by 35
Self-citation
Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Koo, J., Hayashi, M., Verneris, M. R., & Lee‐Sherick, A. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581107 · Cited by 34
Immunotherapy for sarcomas
Nakata, E., Fujiwara, T., Kunisada, T., Ito, T., Takihira, S., & Ozaki, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab005 · Cited by 35
Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies
Zhra, M., Akhund, S. A., & Mohammad, K. S. (2025) · Pharmaceuticals · doi:10.3390/ph18040520 · Cited by 37
Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival
Hung, G., Yen, H., Yen, C., Chen, W., Chen, P. C.-H., Wu, H.-T. H., Chiou, H., Chang, W., & Hsu, H.-E. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4154-z · Cited by 34
Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment
van Maldegem, A. M., Bhosale, A., Gelderblom, H. A. J., Hogendoorn, P. C. W., & Hassan, A. B. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-5 · Cited by 33
Value of ablation therapy in the treatment of lung metastases
Qi, H., & Fan, W. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12567 · Cited by 32
The Use of Phospholipids to Make Pharmaceutical Form Line Extensions
van Hoogevest, P., Tiemessen, H. L. G. M., Metselaar, J. M., Drescher, S., & Fahr, A. (2021) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.202000297 · Cited by 33
Malignant and Metastatic Tumors of the Hand
Puhaindran, M. E., & Athanasian, E. A. (2010) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2010.08.014 · Cited by 32
Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis
Fan, X.-L., Cai, G.-P., Zhu, L.-L., & Ding, G. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s91217 · Cited by 32

Authors: Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., Womer, R. B., Meyers, P. A., & on behalf of the Children's Oncology Group
Affiliations: Memorial Sloan Kettering Cancer Center (US)
The University of Texas MD Anderson Cancer Center (US)
Children's Oncology Group (US)
Mayo Clinic (US)
University of Washington (US)
Johns Hopkins All Children's Hospital (US)
Children's Hospital of Philadelphia (US)
Corresponding author: Meyers, Paul A.
ORCID: Chou, Alexander J.
Kleinerman, Eugenie S.
Krailo, Mark D.
Chen, Zhengjia
Healey, John H.
Conrad, Ernest U.
Womer, Richard B.
Meyers, Paul A.
Venue: Cancer
Publisher: Wiley
Published: 2009-11-03
Volume: 115
Issue: 22
Pages: 5339-5348
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.24566
PMC: PMC2783515
OpenAlex: W2058138047
Cited by: 245
References: 29
Citations by year: 2026: 5 · 2025: 9 · 2024: 8 · 2023: 7 · 2022: 17 · 2021: 19 · 2020: 29 · 2019: 15 · 2018: 14 · 2017: 22 · 2016: 20 · 2015: 19 · 2014: 16 · 2013: 19 · 2012: 7
FWCI: 7.32
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (U10 CA-98413, U10-CA98543, U10CA098413, P01CA106450, U10CA098543)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: muramyl tripeptide phosphatidylethanolamine, metastatic osteosarcoma, ifosfamide, cisplatin, doxorubicin, high-dose methotrexate, event-free survival, overall survival
MeSH terms: Acetylmuramyl-Alanyl-Isoglutamine, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Child, Preschool, Drug Administration Schedule, Female, Humans, Immunologic Factors, Infant, Infant, Newborn, Male, Neoplasm Metastasis, Phosphatidylethanolamines, Osteosarcoma, Survival Analysis, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks